Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients

Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients

Bibliographic Details
Main Authors:	Firouzjaei, A, Li, G-C, Wang, N, Liu, W-X, Zhu, B-M
Format:	Online
Language:	English
Published:	Nature Publishing Group 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895377/

Similar Items

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
by: Messori, Andrea, et al.
Published: (2014)

Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY
Published: (2013)

Independent and Combined Effects of Exercise Training and Metformin on Insulin Sensitivity in Individuals With Prediabetes
by: Malin, Steven K., et al.
Published: (2012)

Synergistic effects of metformin, resveratrol, and hydroxymethylbutyrate on insulin sensitivity
by: Bruckbauer, Antje, et al.
Published: (2013)

Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes
by: Ji, Ming, et al.
Published: (2016)

Pharmacokinetic study of metformin to compare a voglibose/metformin fixed-dose combination with coadministered voglibose and metformin
by: Choi, Hyang-Ki, et al.
Published: (2015)

Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea
by: Kim, Hye-soon, et al.
Published: (2014)

Combined Vildagliptin and Metformin Exert Better Cardioprotection than Monotherapy against Ischemia-Reperfusion Injury in Obese-Insulin Resistant Rats
by: Apaijai, Nattayaporn, et al.
Published: (2014)

Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials
by: Zhu, Hongmei, et al.
Published: (2013)

Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus—the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial
by: Lundby-Christensen, Louise, et al.
Published: (2016)

Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
by: Hostalek, Ulrike, et al.
Published: (2015)

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
by: Jensterle Sever, Mojca, et al.
Published: (2014)

Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes
by: Park, Cheol-Young, et al.
Published: (2014)

Comparative evaluation of efficacy and safety of combination of metformin-vidagliptin versus metfromin-glimepiride in most frequently used doses in patients of type 2 diabetes mellitus with inadequately controlled metformin monotherapy-A randomised open label study
by: Gupta, Shallini, et al.
Published: (2015)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
by: Davies, M J, et al.
Published: (2012)

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
by: Lavalle-González, F. J., et al.
Published: (2013)

Metformin in Gestational Diabetes Mellitus
by: Reece, Sara Wilson, et al.
Published: (2014)

Comment on: TODAY Study Group. Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY. Diabetes Care 2013;36:1749–1757
by: Baldi, James C., et al.
Published: (2013)

Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly
by: Varewijck, A. J., et al.
Published: (2012)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
by: Jeon, Hyun Jeong, et al.
Published: (2011)

Metformin Beyond Diabetes: Pleiotropic Benefits of Metformin in Attenuation of Atherosclerosis
by: Forouzandeh, Farshad, et al.
Published: (2014)

Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT
by: Kahn, Steven E., et al.
Published: (2011)

A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy
by: Gitt, Anselm K, et al.
Published: (2015)

Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants
by: Hivert, Marie-France, et al.
Published: (2016)

Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin
by: Al Omari, Mousa, et al.
Published: (2016)

Impact of Baseline BMI on Glycemic Control and Weight Change with Metformin Monotherapy in Chinese Type 2 Diabetes Patients: Phase IV Open-Label Trial
by: Ji, Linong, et al.
Published: (2013)

Cost of Illness Analysis of Insulin and Insulin-Metformin Combination Usage towards Diabetes Mellitus Type 2 Patients at Hospital in Bandung
by: Mally G. Sholih, et al.
Published: (2018-03-01)

Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
by: Fleming, Joshua W, et al.
Published: (2015)

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
by: White, Judith L, et al.
Published: (2014)

Treatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study
by: Rombopoulos, Grigorios, et al.
Published: (2015)

Metformin vs Insulin in the Management of Gestational Diabetes: A Meta-Analysis
by: Gui, Juan, et al.
Published: (2013)

Could Metformin Manage Gestational Diabetes Mellitus instead of Insulin?
by: Saleh, Hend S., et al.
Published: (2016)

Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk
by: Miele, Luca, et al.
Published: (2015)

Metformin and Cancer in Type 2 Diabetes
by: Park, Hyeong Kyu
Published: (2013)

Risk of Cancer in Diabetes: The Effect of Metformin
by: Malek, Mojtaba, et al.
Published: (2013)

Diabetes, pancreatic cancer, and metformin therapy
by: Gong, Jun, et al.
Published: (2014)

Metformin in gestational diabetes: An emerging contender
by: Singh, Awadhesh Kumar, et al.
Published: (2015)

Insulin and Metformin Regulate Circulating and Adipose Tissue Chemerin
by: Tan, Bee K., et al.
Published: (2009)

Effect of metformin on insulin-resistant endothelial cell function
by: CHEN, HAIYAN, et al.
Published: (2015)

Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study
by: Yoon, Kun Ho, et al.
Published: (2011)